5-Amino-1MQ's US Regulatory Status

5-amino-1MQ (5-amino-1-methylquinolinium) is a small molecule, not a peptide. It is being studied as an inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular NAD+ and methyl-group metabolism. That mechanism is the entire basis for the weight-loss and metabolic claims attached to it online, and it comes almost entirely from cell and rodent studies, not from trials in people (Ruf et al., 2018, mouse diet-induced obesity model; Neelakantan et al., 2018, small molecule inhibitor development).

Is 5-amino-1MQ FDA approved?

No. There is no FDA-approved drug product containing 5-amino-1MQ for any indication, including weight loss, muscle preservation, or metabolic syndrome. Nothing in the available pharmacology or pharmacokinetic literature changes that; a rat bioavailability study is not a path to approval, it is early-stage tool data (LC-MS/MS pharmacokinetic study in rats, 2021). Any product claiming FDA approval or clearance is misrepresenting its status.

Is 5-amino-1MQ on the 503A bulks list?

No, 5-amino-1MQ is not on the FDA's list of bulk drug substances that compounding pharmacies may use under Section 503A of the FD&C Act. That list determines which unapproved active ingredients a licensed 503A pharmacy can legally compound into a patient-specific prescription. You can review the current list and its criteria directly on the FDA's 503A bulk drug substances page. Because 5-amino-1MQ is absent from it, a compounding pharmacy operating under the standard 503A framework has no lawful basis to formulate it as a compounded drug for you. This is a narrow, factual point about one list; it is not a statement about any other regulatory category, and we are not making claims here about FDA Category 2 status or any foreign approval, since those are separate questions this page does not have verified source material to answer.

Why is it sold as a "research chemical" instead?

Vendors label 5-amino-1MQ as "not for human consumption" or "for research use only" largely because that framing sits outside FDA drug regulation, not because it reflects how the product is actually used or marketed. In practice, many of these listings are promoted with dosing suggestions, testimonials, and weight-loss framing aimed squarely at individual buyers, which is the pattern regulators associate with unapproved drug marketing dressed up as lab-supply commerce. The research-chemical label does not mean the material has been quality-tested for human use, dosed safely, or manufactured under pharmaceutical-grade controls. It is a liability shield, not a safety signal.

What does the underlying science actually show?

The mechanistic case for NNMT inhibition is real and reasonably active in preclinical pharmacology. NNMT sits at a metabolic crossroads involving NAD+ salvage and one-carbon metabolism, and its expression rises in obesity-related tissue states (NNMT at the crossroads of metabolism and epigenetics, 2021; NNMT in obesity and type 2 diabetes, 2021). Selective small-molecule NNMT inhibitors, including compounds structurally related to 5-amino-1MQ, have reversed high-fat-diet-induced weight gain in mice and improved metabolic markers in rodent models (membrane-permeable NNMT inhibitors reverse HFD obesity in mice, 2018; NNMT inhibition and obesity-related metabolic dysfunction, 2024; NNMT as a metabolic syndrome target, 2024). That is a legitimate and still-developing research thread. It is also, as of now, entirely preclinical. No published human trial establishes that 5-amino-1MQ produces weight loss, improves insulin sensitivity, or is safe at any specific dose in people. For a fuller look at the mechanism and the evidence gap, see our pages on NNMT inhibition mechanism and weight-loss evidence.

What are the practical risks of buying an unregulated compound?

Because 5-amino-1MQ falls outside both FDA drug approval and the 503A compounding pathway, there is no regulatory checkpoint verifying identity, purity, sterility, or labeled concentration for products sold under this name. Reported issues with unregulated research-chemical markets generally include mislabeled concentrations, contamination, and inconsistent sourcing, none of which have been formally studied for this specific compound in the sources available here, so treat that as a general market risk rather than a documented finding about this product. Anyone considering use should also weigh that dosing information circulating online is not derived from human trials and cannot be treated as clinical guidance; our dosing claims and side effects and safety pages walk through what is and is not known.

A quick verification checklist before you evaluate any 5-amino-1MQ product

Use these four questions to separate a straightforward research-chemical listing from a mislabeled drug marketing claim:

1. Does the listing claim FDA approval, clearance, or "pharmaceutical grade" status? If yes, that claim is false on its face; no such approval exists.
2. Does the seller reference compounding, a prescription, or a pharmacy fill? No 503A pharmacy can lawfully compound 5-amino-1MQ under the current bulks list, so any prescription framing should be treated as a red flag rather than reassurance.
3. Does the marketing include specific human dosing, before/after outcomes, or patient testimonials? That is inconsistent with a genuine research-only product and suggests unapproved drug marketing.
4. Is there any third-party purity or identity testing disclosed, independent of the seller? Absence of this does not confirm a problem, but its presence is the only concrete signal available in an unregulated market.

None of these four checks tell you whether 5-amino-1MQ is safe or effective. They only tell you whether a given seller is being straightforward about what it is not.

What is established versus what is not

Established: 5-amino-1MQ has no FDA-approved indication, is not on the 503A bulks list, and its human safety and efficacy data are not published in controlled trials. Plausible but unproven: NNMT inhibition as a mechanism for improving diet-induced metabolic dysfunction, based on consistent rodent findings across multiple independent labs. Not established: any specific human dose, any human safety profile, any comparative claim against approved therapies. For readers weighing this against approved options, our 5-amino-1MQ versus GLP-1 comparison lays out that contrast directly, and the FDA Peptide Status Tracker is a useful reference point even though 5-amino-1MQ itself is a small molecule rather than a peptide.

When should you involve a clinician instead of a vendor?

If you are considering 5-amino-1MQ for weight management or metabolic concerns, that is a conversation for a physician who can review your actual metabolic history, current medications, and approved treatment options, not a research-chemical listing page. If you experience any adverse reaction after using an unregulated compound, whether that is unusual heart rate, severe gastrointestinal symptoms, or signs of an allergic reaction, seek urgent medical care and bring the product's packaging or listing information with you, since standard toxicology screens will not automatically identify a research chemical.